Format

Send to

Choose Destination
Nanomedicine (Lond). 2018 Mar 1;13(6):595-603. doi: 10.2217/nnm-2017-0315. Epub 2018 Jan 30.

Irinotecan/IR-820 coloaded nanocomposite as a cooperative nanoplatform for combinational therapy of tumor.

Li T1, Shen X1, Xie X1, Chen Z1, Li S1,2, Qin X1,2, Yang H1,2, Wu C1,2, Liu Y1,2.

Author information

1
Department of Biophysics, School of Life Science & Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China.
2
Center for Information in Biology, University of Electronic Science & Technology of China, Chengdu 610054, Sichuan, PR China.

Abstract

AIM:

To enhance synergistic therapeutic effects in breast cancer therapy. Here, we used hollow mesoporous silica nanoparticles as a biocompatible carrier to coload chemotherapy drugs Irinotecan and near-infrared IR-820 dye, which enhanced antitumor efficacy by combining chemotherapy and phototherapy.

METHODS:

The successful synthesis of hollow mesoporous silica nanoparticles/Irinotecan/IR820 (HMII) nanocomplex was confirmed by Fourier  transform infrared spectroscopy and Fluorescence spectra. The photothermal conversion efficiency and antitumor efficiency in murine breast cancer cells (EMT-6) bearing mice were further evaluated.

RESULTS:

The results demonstrated that HMII enhanced the delivery of Irinotecan and IR-820 into EMT-6 cells. HMII generated a high temperature upon a near-infrared laser irradiation (808 nm), and showed higher therapeutic efficacy in EMT-6-bearing mice compared with either HMII without laser or free drug with a laser.

CONCLUSION:

HMII is a desired drug codelivery system to efficiently inhibit the growth of breast cancer.

KEYWORDS:

HMSNs; IR820; Irinotecan; codelivery; combinational therapy

PMID:
29381122
DOI:
10.2217/nnm-2017-0315
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center